Impact and Outcomes of Pretreatment Total Serum Testosterone on Localized Prostate Cancer Patients

Table. 1

Clinical demographic features of the study population.

	All patients	Unweighted baseline cohort									Propensity-weighted cohort
		Testosterone cohort			Absolute standardized difference			value			Absolute standardized difference			value
Cohort		1	2	3	1vs2	1vs3	2vs3	1vs2	1vs3	2vs3	1vs2	1vs3	2vs3	1vs2	1vs3	2vs3
	Total	100–239	240–593	594+
# of patients	258	39	176	43
Age (yrs)		63.9	65.4	64.5	0.20	0.08	0.12	0.21	0.69	0.48	0.11	0.03	0.08	0.56	0.89	0.64
	%	%	%	%
ADT used with therapy
ADT used	19	10.3	18.8	27.9	0.21	0.44	0.23	0.21	0.05	0.19	0.16	0.16	0.00	0.47	0.07	0.98
No ADT	81	89.7	81.3	72.1	0.21	0.44	0.23				0.16	0.16	0.00
NCCN-risk group
High/VH risk	20.9	23.1	21	18.6	0.05	0.11	0.06	0.29	0.89	0.27	0.10	0.00	0.10	0.85	0.97	0.72
Intermediate risk	50.4	41	54	44.2	0.26	0.06	0.20				0.01	0.05	0.06
Low risk	28.7	35.9	25	37.2	0.24	0.03	0.27				0.09	0.06	0.15
Therapy
Brachytherapy	57.8	59	56.8	60.5	0.04	0.03	0.07	0.62	0.14	0.40	0.15	0.1	0.05	0.60	0.70	0.95
EBRT	16.3	23.1	17	7	0.17	0.45	0.28				0.02	0.12	0.11
EBRT + LDR	14	7.7	14.2	18.6	0.18	0.31	0.12				0.03	0.04	0.01
Surgery	12	10.3	11.9	14	0.05	0.11	0.06				0.21	0.24	0.03
ISUP grade group
Group 1,2		76.9	68.8	65.1	0.18	0.25	0.08	0.19	0.26	0.82
Group 3		5.1	16.5	16.3	0.31	0.30	0.01
Group 4,5		17.9	14.8	18.6	0.09	0.02	0.11
Clinical T-stage
T1c	20.9	51.3	63.6	55.8	0.26	0.09	0.16	0.25	0.92	0.45
T2	50.4	41	33	37.2	0.17	0.08	0.09
T3a/b	28.7	7.7	3.4	7	0.22	0.04	0.18
Body mass index
25–29.9	18.6	20.5	17.6	20.9	0.08	0.01	0.09	0.9119	0.53	0.338
30+	15.9	15.4	18.2	7	0.08	0.23	0.31
<25	7.4	7.7	6.8	9.3	0.03	0.06	0.10
Unknown	58.1	56.4	57.4	62.8	0.02	0.04	0.05
Smoking history
Current	7	7.7	5.1	14	0.10	0.25	0.35	0.54	0.57	0.24
Former	24.8	33.3	23.9	20.9	0.22	0.29	0.07
Never	50.4	43.6	52.3	48.8	0.17	0.11	0.07
Unknown	17.8	15.4	18.8	16.3	0.09	0.02	0.06
Pre-treatment PSA
10–20	32.2	41	31.3	27.9	0.21	0.29	0.07	0.43	0.46	0.79
<10	59.7	53.8	59.7	65.1	0.12	0.23	0.11
>20	8.1	5.1	9.1	7	0.14	0.07	0.08

values for the demographics are calculated based on the chi-squared test. Clinical T-stage derived from the American Joint Committee on Cancer (AJCC) 8^th edition. Comparison of standardized difference for the unweighted and propensity weight populations used in the analyses are shown. EBRT = external beam radiation therapy, VH=very high, GS = Gleason score, ADT = Androgen deprivation therapy, ISUP = International Society of Urological Pathologists.